News | March 14, 2024
Zydus launches generic version of Olaparib ‘IBYRA’ in India
The drug will target specific genetic mutations prevalent in certain types of cancers
The drug will target specific genetic mutations prevalent in certain types of cancers
It is the first autotaxin inhibitor to be investigated in cancer patients
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Subscribe To Our Newsletter & Stay Updated
